Literature DB >> 28835723

Targeting neoantigens to augment antitumour immunity.

Mark Yarchoan, Burles A Johnson, Eric R Lutz, Daniel A Laheru, Elizabeth M Jaffee.   

Abstract

Year:  2017        PMID： 28835723     DOI： 10.1038/nrc.2017.74

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  1 in total

Review 1.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716
  1 in total
  41 in total

Review 1.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

2.  PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

Authors:  Mark Yarchoan; Lee A Albacker; Alexander C Hopkins; Meagan Montesion; Karthikeyan Murugesan; Teena T Vithayathil; Neeha Zaidi; Nilofer S Azad; Daniel A Laheru; Garrett M Frampton; Elizabeth M Jaffee
Journal:  JCI Insight       Date:  2019-03-21

Review 3.  Impact of oncogenic pathways on evasion of antitumour immune responses.

Authors:  Stefani Spranger; Thomas F Gajewski
Journal:  Nat Rev Cancer       Date:  2018-01-12       Impact factor: 60.716

Review 4.  Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.

Authors:  Julie M Collins; Jason M Redman; James L Gulley
Journal:  Expert Rev Vaccines       Date:  2018-08-22       Impact factor: 5.217

Review 5.  Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies.

Authors:  Michael Rückert; Lisa Deloch; Rainer Fietkau; Benjamin Frey; Markus Hecht; Udo S Gaipl
Journal:  Strahlenther Onkol       Date:  2018-03-02       Impact factor: 3.621

Review 6.  Industrializing engineered autologous T cells as medicines for solid tumours.

Authors:  Cedrik M Britten; Aiman Shalabi; Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2021-04-08       Impact factor: 84.694

Review 7.  Treatment strategies for DNA repair-deficient prostate cancer.

Authors:  Benjamin A Teply; Emmanuel S Antonarakis
Journal:  Expert Rev Clin Pharmacol       Date:  2017-06-12       Impact factor: 5.045

Review 8.  Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.

Authors:  Wei Wang; Xuefang Cao
Journal:  Crit Rev Immunol       Date:  2019       Impact factor: 2.214

9.  Reconstruction and Analysis of the Immune-Related LINC00987/A2M Axis in Lung Adenocarcinoma.

Authors:  Jiakang Ma; Xiaoyan Lin; Xueting Wang; Qingqing Min; Tonglian Wang; Chaozhi Tang
Journal:  Front Mol Biosci       Date:  2021-04-27

10.  Enhanced Antitumor Response to Immune Checkpoint Blockade Exerted by Cisplatin-Induced Mutagenesis in a Murine Melanoma Model.

Authors:  Falih M Gorgun; Steven G Widen; Douglas S Tyler; Ella W Englander
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.